Although high PCNA expression alone predicts poor survival (P=0.0144, Log-rank test) in breast cancer patients (Fig. 7d), combining PCNA and metastatic signature together very improves the poor survival prediction (P=1.018e−4, Log-rank test) in the same cancer patients (Fig. 7e). This evidence concerns the gene PCNA and breast carcinoma.